These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26093618)

  • 21. Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70.
    Shevtsov MA; Pozdnyakov AV; Mikhrina AL; Yakovleva LY; Nikolaev BP; Dobrodumov AV; Komarova EY; Meshalkina DA; Ischenko AM; Pitkin E; Guzhova IV; Margulis BA
    Int J Cancer; 2014 Nov; 135(9):2118-28. PubMed ID: 24691976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of immunotherapy and gene therapy for high-grade gliomas.
    Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
    Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine therapies in malignant glioma.
    Oh T; Sayegh ET; Fakurnejad S; Oyon D; Lamano JB; DiDomenico JD; Bloch O; Parsa AT
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):508. PubMed ID: 25431096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in heat shock protein-based cancer vaccines.
    Wang HH; Mao CY; Teng LS; Cao J
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):22-7. PubMed ID: 16481277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation.
    Murshid A; Gong J; Calderwood SK
    Expert Rev Vaccines; 2008 Sep; 7(7):1019-30. PubMed ID: 18767951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide vaccines for the treatment of glioblastoma.
    Swartz AM; Batich KA; Fecci PE; Sampson JH
    J Neurooncol; 2015 Jul; 123(3):433-40. PubMed ID: 25491947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
    Aalamian M; Fuchs E; Gupta R; Levey DL
    Urol Oncol; 2006; 24(5):425-33. PubMed ID: 16962495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside.
    Hoos A; Levey DL; Lewis JJ
    Dev Biol (Basel); 2004; 116():109-15; discussion 133-43. PubMed ID: 15603187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications.
    Hoos A; Levey DL
    Expert Rev Vaccines; 2003 Jun; 2(3):369-79. PubMed ID: 12903802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat shock protein vaccines: from bench to bedside.
    Binder RJ
    Int Rev Immunol; 2006; 25(5-6):353-75. PubMed ID: 17169780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hsp-based tumor vaccines: state-of-the-art and future directions.
    Takakura Y; Takemoto S; Nishikawa M
    Curr Opin Mol Ther; 2007 Aug; 9(4):385-91. PubMed ID: 17694451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.